On September 3, 2026, Apogee Therapeutics completed its merger with Andor LLC, a subsidiary of AbbVie Inc., becoming an indirect wholly owned subsidiary. Shareholders received $135.11 per share in cash, excluding those holding appraisal rights or affiliated entities. The transaction carries a total equity value of approximately $10.9 billion and was funded by AbbVie using cash on hand and debt. Concurrently, all directors and executive officers resigned from the board and management positions. Apogee Therapeutics Common Stock was suspended from trading on Nasdaq effective September 4, 2026, with plans to file Form 15 to terminate registration under Section 12(g) of the Securities Exchange Act. The company operates in the biotechnology industry, focusing on developing novel therapies for inflammatory and immune-mediated diseases.

Apogee Therapeutics stockholders approved the proposed merger with AbbVie subsidiary Andor LLC at a special meeting on August 11, 2026. The Merger Proposal received 46,508,107 votes in favor against 3,885 opposed and 14,261 abstentions, representing approximately 74.87% of outstanding voting shares present or represented by proxy. This approval satisfies a closing condition for the transaction, which will result in Apogee becoming an indirect wholly-owned subsidiary of AbbVie. Conversely, the advisory vote on merger-related executive compensation was rejected, with 27,123,259 votes against and only 19,323,605 in favor. In connection with the anticipated closing, all eight current directors have indicated their intention to resign effective upon the Merger's completion. Apogee Therapeutics is a biopharmaceutical company focused on developing treatments for inflammatory diseases.

Apogee Therapeutics reported second quarter 2026 financial results and announced that AbbVie will acquire the company for $135.11 per share in cash, representing a total equity value of approximately $10.9 billion. The transaction is expected to close in the third quarter of 2026, subject to shareholder approval and regulatory clearance. Financially, the company reported a net loss of $85.9 million for the quarter ended June 30, 2026, compared to a net loss of $66.1 million in the prior year period. Research and development expenses increased to $67.3 million from $55.7 million, while general and administrative expenses rose to $24.3 million from $17.5 million. Cash and equivalents stood at $1.3 billion as of June 30, 2026. Additionally, the company highlighted positive Phase 2 results for its lead asset zumilokibart in atopic dermatitis and announced plans to initiate Phase 3 trials this year.

Apogee Therapeutics, Inc. entered into a merger agreement with Andor LLC and AbbVie Inc. to be acquired in a cash transaction for $135.11 per share. The deal is subject to stockholder approval and regulatory clearances. Apogee Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics.

On June 17, 2026, Apogee Therapeutics entered into an antibody discovery agreement and a contemporaneous license agreement with Paragon Therapeutics, Inc. Paragon will generate and characterize monospecific antibody candidates directed to interleukin 31 receptor (IL-31R), with Apogee paying monthly research fees and potential CMC activity fees between $1.3 million and $2.0 million. Apogee acquired an exclusive, worldwide, royalty-bearing license to exploit antibodies discovered under the agreement, with potential milestone payments to Paragon totaling up to $23.25 million, including $5.25 million upon the first human dose in a Phase I trial. The agreement includes low-single digit royalties on net sales. Apogee operates in the biotechnology industry and develops therapeutic antibodies.